首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL-15 |
| Uniprot No | P40933 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 49-162aa |
| 氨基酸序列 | NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVI SLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFL QSFVHIVQMFINTS |
| 预测分子量 | 13 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-15重组蛋白的3篇代表性文献(内容基于真实研究概括，具体信息建议通过数据库核实)：
---
1. **文献名称**: *"IL-15 in the life and death of lymphocytes: immunotherapeutic implications"*
**作者**: Waldmann TA, et al.
**摘要**: 综述IL-15通过激活CD8+ T细胞和NK细胞增强抗肿瘤免疫的作用机制，探讨重组IL-15在癌症免疫治疗中的潜力，以及与IL-2的功能差异。
2. **文献名称**: *"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human IL-15 in patients with cancer"*
**作者**: Conlon KC, et al.
**摘要**: 首次报道重组人IL-15的I期临床试验结果，证明其可安全扩增并激活外周NK细胞和CD8+ T细胞，为实体瘤和血液肿瘤治疗提供依据。
3. **文献名称**: *"Design of a stabilized cytokine-receptor complex for improved cancer immunotherapy"*
**作者**: Zhu X, et al.
**摘要**: 通过结构工程将IL-15与IL-15Rα融合，形成长效复合物(IL-15N72D/IL-15Rα-Fc)，显著提高体内半衰期和抗肿瘤活性，优于天然IL-15.
---
**备注**：IL-15研究多聚焦于其与受体结合优化(如“超级激动剂”)、临床转化(如与PD-1抑制剂联用)及免疫毒性控制。建议通过PubMed或Web of Science以“recombinant IL-15”、“IL-15 immunotherapy”为关键词筛选最新进展。
**Background of IL-15 Recombinant Protein**
Interleukin-15 (IL-15) is a pleiotropic cytokine critical for regulating innate and adaptive immune responses. Structurally, it belongs to the four-α-helix bundle cytokine family and shares receptor components with IL-2. including the β (CD122) and γ (CD132) chains, but utilizes a unique α chain (IL-15Rα) for specific signaling. This distinction enables IL-15 to promote the survival, proliferation, and activation of key immune cells—such as natural killer (NK) cells, CD8+ memory T cells, and innate lymphoid cells—without inducing regulatory T cell expansion, a limitation seen with IL-2.
Recombinant IL-15 protein, produced via genetic engineering in systems like *E. coli* or mammalian cells, retains the native cytokine's bioactivity. Its therapeutic potential is driven by its ability to enhance antitumor immunity. Preclinical studies demonstrate that IL-15 stimulates NK cell-mediated tumor cytotoxicity and sustains CD8+ T cell persistence, making it a promising candidate for cancer immunotherapy. Clinical trials are exploring its efficacy in treating malignancies like melanoma and renal cell carcinoma, often in combination with checkpoint inhibitors or adoptive cell therapies.
Beyond oncology, IL-15 recombinant protein is investigated for treating viral infections (e.g., HIV) and immune deficiencies due to its role in maintaining lymphocyte homeostasis. Challenges remain, however, including its short half-life *in vivo* and dose-limiting toxicities such as hypotension or cytokine release syndrome. To address these, engineered variants (e.g., IL-15/IL-15Rα fusion proteins) and targeted delivery systems (nanoparticles, antibody-cytokine conjugates) are under development to improve pharmacokinetics and reduce off-target effects.
Overall, IL-15 recombinant protein represents a versatile immunomodulatory tool, bridging gaps in current therapeutic strategies by selectively amplifying protective immune responses while minimizing adverse outcomes.
×
